Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27218626 | 0.85 | CYP11B1 (0.50) | CYP11B1MPOHSD11B1PLCG1LRRK2 | |
| SCHEMBL1007086 | 0.80 | CYP11B1 (0.53) | CYP11B1MPOHSD11B1PLCG1LRRK2 | |
| SCHEMBL6109965 | 0.80 | CYP11B1 (0.53) | CYP11B1MPOHSD11B1PLCG1CYP1A2 | |
| SCHEMBL129267 | 0.80 | CYP11B1 (0.53) | CYP11B1MPOHSD11B1PLCG1LRRK2 | |
| SCHEMBL1543531 | 0.80 | CYP11B1 (0.53) | CYP11B1MPOHSD11B1PLCG1LRRK2 | |
| SCHEMBL25347053 | 0.80 | CYP11B1 (0.53) | CYP11B1MPOHSD11B1PLCG1LRRK2 | |
| SCHEMBL1007759 | 0.80 | CYP11B1 (0.53) | CYP11B1MPOHSD11B1PLCG1LRRK2 | |
| SCHEMBL30748563 | 0.80 | CYP11B1 (0.53) | CYP11B1MPOHSD11B1PLCG1LRRK2 | |
| Hydrochloric Acid SCHEMBL3288938 | 0.78 | CYP11B1 (0.51) | CYP11B1MPOHSD11B1PLCG1LRRK2 | |
| Hydrochloric Acid SCHEMBL26104353 | 0.78 | CYP11B1 (0.51) | CYP11B1MPOHSD11B1PLCG1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | disclosed |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-09-02 | — | — | US | disclosed |
| US-20250197368-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | DRAIG THERAPEUTICS LTD. (GB) | 2025-06-19 | — | — | US | disclosed |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-20250084077-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-28 | — | — | US | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240336602-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2024-10-10 | — | — | US | disclosed |
| US-12091409-B2 | Ether linked triazoles as NRF2 activators | ASTEX THERAPEUTICS LIMITED (GB) | 2024-09-17 | — | — | US | disclosed |
| EP-0586560-A1 | NOVEL BENZOPYRIDO PIPERIDYLIDENE COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE AND METHODS OF USE | SCHERING CORPORATION (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0556813-A1 | Amphoteric tricyclic compounds as antihistaminic and antiallergic agents | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-25 | — | — | EP | disclosed |
| WO-1993002081-A1 | NOVEL BENZOPYRIDO PIPERYLIDENE COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE AND METHODS OF USE | SCHERING CORPORATION (US) | 1993-02-04 | — | — | WO | disclosed |
| EP-0524784-A1 | Benzopyrido piperidylidene compounds as PAF antagonists | SCHERING CORPORATION (US) | 1993-01-27 | — | — | EP | disclosed |
| WO-1992020681-A1 | NOVEL BENZOPYRIDO PIPERIDYLIDENE COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE AND METHODS OF USE | SCHERING CORPORATION (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0515158-A1 | Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use | SCHERING CORPORATION (US) | 1992-11-25 | — | — | EP | disclosed |
| US-5104876-A | Antiallergens, antiinflammatory agent | SCHERING CORPORATION | 1992-04-14 | — | — | US | disclosed |
| EP-0411048-A1 | NOVEL BENZOPYRIDO PIPERIDINE, PIPERIDYLIDENE AND PIPERAZINE COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE AND METHODS OF USE | SCHERING CORPORATION (US) | 1991-02-06 | — | — | EP | disclosed |
| EP-0341860-A1 | Benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use | SCHERING CORPORATION (US) | 1989-11-15 | — | — | EP | disclosed |
| WO-1989010369-A1 | NOVEL BENZOPYRIDO PIPERIDINE, PIPERIDYLIDENE AND PIPERAZINE COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE AND METHODS OF USE | SCHERING CORPORATION (US) | 1989-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | CYP11B1 1764/4885MPO 1111/4885HSD11B1 3323/4885 |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | CYP11B1 567/4885MPO 2248/4885HSD11B1 2671/4885 |
| US-20250084077-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | CYP11B1 22/4885MPO 364/4885HSD11B1 176/4885 |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | CYP11B1 1764/4885MPO 1111/4885HSD11B1 3323/4885 |
| US-20250197368-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | GABRA2, GABRA3, GABRB2 | CYP11B1 595/4885MPO 4417/4885HSD11B1 1197/4885 |
| US-12091409-B2 | Ether linked triazoles as NRF2 activators | NFE2L2, KEAP1, NQO1 | CYP11B1 22/4885MPO 364/4885HSD11B1 176/4885 |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | CYP11B1 567/4885MPO 2248/4885HSD11B1 2671/4885 |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM6, TRPV3, TRPM2 | CYP11B1 757/4885MPO 1128/4885HSD11B1 1062/4885 |
| US-20240336602-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM6, TRPM2 | CYP11B1 1764/4885MPO 1111/4885HSD11B1 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.